



## Bovine *Streptococcus uberis* Intramammary Infections and Mastitis

Volker Kromker<sup>1\*</sup>, Friederike Reinecke<sup>2</sup>, Jan-Hendrik Paduch<sup>1</sup> and Nils Grabowski<sup>3</sup><sup>1</sup>University of Applied Sciences and Arts, Faculty II, Microbiology, Hannover, Germany<sup>2</sup>Udder Health Services, Chamber of Agriculture Lower Saxony, Oldenburg, Germany<sup>3</sup>Institute of Food Quality and Food Safety, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany**\*Corresponding author:** Volker Kromker, Microbiology, Faculty of Mechanical and Bioprocess Engineering, University of Applied Sciences and Arts, Heisterbergallee 12, 30453 Hannover, Germany, Tel: +49 511 9296-2205; Fax: +49 511 9296-2210; E-mail: [volker.kroemker@hs-hannover.de](mailto:volker.kroemker@hs-hannover.de)**Rec date:** Apr 25, 2014; **Acc date:** Jun 26, 2014; **Pub date:** Jun 30, 2014**Copyright:** © 2014 Kromker V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Abstract

*Streptococcus (S.) uberis* is a causative agent for clinical and subclinical bovine mastitis which significance for the udder health has increased over the last decades. Molecular diagnosis methods revealed that *S. uberis* may be subdivided into many different varieties with different epidemiological properties. In addition, some varieties were reclassified as *Streptococcus parauberis* and *Globicatella sanguinis*. The present paper reviews *S. uberis* and its role in modern dairy farming. This pathogen is ubiquitous for which it is considered as environment-associated. Straw bedding and pasture, but also the bovine skin and digestive mucosae are typical localizations inhabited by *S. uberis*. Due to its capacity to persist within the mammary tissue, some infections may eventually turn cow-associated. In other cases, the infection is short, but in any case, there is a high risk of re-infection. Although many varieties remain susceptible to most antimicrobial agents, the problem for the dairy farm lies in the high rate of re-infection. This paper also reviews risk factors, therapies and measures to control *S. uberis* at farm level.

**Keywords:** *Streptococcus uberis*; Microorganism; Cellobiose

### Introduction

Mastitis caused by *Streptococcus (S.) uberis* has been detected increasingly in dairy farms. This species is known to cause both clinical and subclinical infections of the bovine udder and represents the leading pathogen in a growing amount of dairy herds.

The present paper is intended as a literature review regarding the properties, the ways of diagnosis and the possible strategies to combat this microorganism. The more risk factors that favour the development of the disease are known, the more efficient advice can be provided to the farmer.

### Properties and diagnosis

*S. uberis* [1] is classified within the order Lactobacillales and the family Streptococcaceae. There have been many ways to classify streptococci. One of the first was the Lancefield grouping which is based on serology. In the original paper [2], *S. uberis* (which was described in 1932) was not mentioned expressly, but all corresponding strains (group E) originated from bovine milk. However, not all *S. uberis* strain can be classified as group E, so that other authors [3] consider it as a part of group G. Many Lancefield groups (including E) were later merged to a “pyogenic group”, along with other typical animal pathogens, e.g. *S. dysgalactiae*, *S. agalactiae*, *S. canis*, and *S. equi* [4]. Nowadays, molecular biology methods, e.g. DNA-DNA reassociation or 16S rDNA gene sequencing, are used to classify the different species. *S. uberis*, which also belongs to the pyogenic group, acts as the sister clade to the species mentioned before, as was demonstrated by Täpp et al. [5] who sequenced the RNase P RNA gene *rnpB*. From the clinical point of view, Facklam [4] chose another way of classification which is based on phenotype. Being

human-based, *S. uberis* was classified as an “unusual *Streptococcus* species”.

The bacterium is Gram-positive, aerotolerant and anaerobic. The cells are coccoid (diameter 0.5 to 1 µm) and occur in pairs or in chains. On blood agar plates, *S. uberis* grows at 30 to 37°C. Colonies have a diameter of 1 to 2 mm after an incubation period of 24 to 48 h. Providing 0.1% aesculin to the medium enhances bacteria identification, as *S. uberis* and enterococci hydrolyse aesculin to glucose and aesculetin. Previously, *S. uberis* was divided into two different serotypes, I and II, both having been isolated from cases of bovine mastitis. The latter was reclassified as *S. parauberis* [6], while all the *S. uberis*-like strains isolated from human cases were merged in *Globicatella sanguinis* [3].

Among 1,894 isolates of aesculin-positive streptococci, 82.3% were identified as *S. uberis* [7]; no data was provided on the origin of these strains. On the other hand, some papers indicate that approx. 83% of *S. uberis* isolates are also aesculin-positive [8,9], while others [10,11] demonstrated that all strains are capable of hydrolysing aesculin. When growing on blood agar plates, *S. uberis* displays either a weak α- or γ-haemolysis [12]. Approx. 95% of *S. uberis* isolates are positive for β-galactosidase which can be used to tell them apart aesculin-hydrolyzing enterococci. Watts et al. [13] recommended a modified Rambach agar for identification on which *S. uberis* colonies grow with a blue colour. In comparison, colonies of *S. agalactiae*, *S. dysgalactiae*, *Enterococcus (E.) saccharolyticus* or *E. faecalis* do not metabolize propylenglycol (red colonies) and do not produce β-galactosidase [13]. *S. uberis* produces acids out of cellobiose, aesculin, glucose, fructose, galactose, inulin, maltose, mannitol, mannose, ribose, salicin, sorbitol, starch, sucrose and trehalose [9]. Its growth was observed in 4%, but neither in 6.5% NaCl nor at a pH of 9.6. Telling *S. uberis* from enterococci is also possible applying the Sherman criteria. *S. uberis* grows slowly or ceases to do so at ≤ 10°C and ≥ 45°C. Microorganisms become inactivated after heating to 60°C for 30 minutes [12]. Recently,

a scheme based on eleven biochemical tests was recommended to identify *S. uberis* [9], i.e. the Christie-Atkins-Munch-Petersen reaction (81% of tested *S. uberis* were negative), arginin hydrolysis (83% negative), aesculin (89% positive) and sodium hippurate (96% positive), growth in an inulin-containing medium (64% positive), usage of mannitol (98% positive), raffinose (94% negative), salicin (94% positive) and sorbitol (96% positive) as a source for carbohydrates, growth at 45°C (98% negative) and in 6.5% NaCl (100% negative).

*S. uberis* is a serologically heterogeneous species [12]. This is a key fact to notice as this heterogeneity leads to marked differences regarding the pathogen's epidemiological properties [14]. It is not possible to differentiate between *S. uberis* and *S. parauberis*, which was described in the year 1990 [6] using phenotypic methods [4]. As shown by Zadoks et al. [15], a few *S. uberis* strains isolated from milk are closely related to *S. parauberis*. Species-specific primers for the detection of *S. uberis* on species level via molecular probes reacting in PCR are described by several authors [16,17]. Forsman et al. [16] used the primer pair STRU-UbI and STRU-UbII (size of the main PCR product: 330 bp) to detect *S. uberis* with a high degree of reliability, while Riffon et al. [17] worked with the primers Sub 302, 396, 1546, and 2170, based on GI no. 43370 and 2668550 (23S rDNA) in order to design a culture-independent PCR diagnosis kit. Pulsed-field gel electrophoresis and random amplified polymorphic DNA fingerprinting are used to evaluate the diversity of strains of *S. uberis* which in turn reflects its adaptability to the udder [18-20]. In addition, multilocus sequence typing is used to characterize *S. uberis* populations as well as the epidemiological properties of this pathogen [21,22], i.e. the loci arc, ddl, gki, recP, ddk, tpi, yqiL, hasA, and hasC (225 to 793 bp amplicon size).

Primers used for PCR include ub-I and ub-II (for the rRNA target gene 16S), ub-23S-I and ub-23S-II (for 23S) as well as STRU-Ub-I and STRU-Ub-II (for the 16S-23S intergenic spacer [23]).

### Virulence factors

The factors of virulence are not known completely and it is suggested that their expression varies from one strain to the other [24,25]. *S. uberis* is able to adhere to and invade in mammary epithelia cells [26-28]. Adherence and invasion can be attributed to the “*S. uberis* adhesion molecule” (SUAM) [29]. According to Frost et al. [30], the high prevalence of *S. uberis* in some dairy herds may be explained by the ability to adhere to host cells. The enzymes of *S. uberis* seem to affect strongly the dissemination of infections caused by it [28]. All strains produce free hyaluronidase that enhances the distribution of the pathogen within tissues [24,28]. According to Matthews et al. [26], the hyaluronidase synthesized by *S. uberis* is capable of preventing the proliferation of a line of udder epithelial cells. Another factor of virulence could be its capability to produce hyaluronic acid capsules [25]. Matthews et al. [25] indicated that 44% of *S. uberis* strains isolated from bovine udders provoked these capsules. Crowley et al. [31] showed that clinical isolates produce more biofilm biomass than a strain from a healthy cow. *S. uberis* binds lactoferrin to obtain iron required for bacterial growth [32]. Besides that, a plasminogen activator factor and a CAMP factor have also been recorded [33]. In fact, Tassi et al. [34] could show that *S. uberis* strains may also be differentiated into host-adapted, pathogenic strains, and non-adapted, basically apathogenic strains.

## Epidemiology

### Habitats and reservoirs

*S. uberis* is no mastitis pathogen that is obligatorily adapted to the udder. In fact, it is a ubiquitous microorganism which colonizes animals as well as their environment [35,36]. It has been localized on the animals' lips, tonsils and skin, inside the oral cavity, rumen, respiratory tract, rectum, on the teat orifice, in teat canals and infected udders, and in faeces and wounds. It appears that *S. uberis* spreads mainly via the mucosae of the digestive tract. Starting from the oral and lips mucosae, the pathogen is distributed via licking into the environment, including fur and epidermis of other cows. Furthermore, bovine faeces (and with that, the intestinal mucosa) also contribute strongly to its dissemination in the environment [36-45]. Despite the detection of *S. uberis* in bovine teat canals, it remains unclear if-unlike cow-associated mastitis pathogens like *Staphylococcus (S.) aureus* and *S. agalactiae*-the environmental-associated pathogen *S. uberis* is able to colonize the teat canal epithelium [46-48].

Hejlícek [43] encountered *S. uberis* in 51.6% of dairy cow skin samples and in 85.8% of environment samples. Zadoks et al. [15] found that it was present in 63% of environment samples (i.e. earth, vegetable material and bedding), in 23% of faeces samples and 4% of milk samples. During summer (grazing season), bovine faeces are more contaminated than in other seasons. Straw and other organic bedding materials enhance the growth of *S. uberis* [36]. Furthermore, approx. 20% of Canadian colostrum samples also contained *S. uberis* [49]. Since samples were drawn from the drinking bottles, the exact origin of these bacteria remains undetermined [49]. Furthermore, it is hypothesized that flies may be a potential reservoir for *S. uberis* [50].

### Infections originated during the dry period

The dry period is the most common portion of the production cycle in which dairy cows acquire an infection with *S. uberis* [51,52]. Frequently *S. uberis* infections are manifested as acute mastitis, usually during the subsequent lactation [46]. Wilkinson [53] calculated that 56% of clinical cases had originated during the dry period. If few strains are found on a single farm, a contagious form is suspected. If several cows of a herd were infected, it is relatively improbable that all infections were caused by the same strain. Infections caused by one dominating *S. uberis* strain are more persistent than those by several minor strains.

Due to its biochemical abilities and the ability to invade in mammary gland cells and to its capacity to produce biofilms and capsule forming it was suggested that *S. uberis* can persist in infected bovine udders. This promotes the development of chronic infections of the mammary gland and allows the pathogen to turn from environment-associated to cow-associated [54].

### Intramammary infections and mastitis

Mammary epithelial cells are involved in inflammatory processes [55,56]. In comparison to *Escherichia (E.) coli*, *S. uberis* induces a delayed mRNA expression of interleukin-8 by epithelial cells [56]. This cytokine is involved in the recruitment of neutrophils [57]. Tassi et al. [31] observed that neutrophils, lymphocytes and interleukin-17A may play roles in the healing of intramammary *S. uberis* infections.

Numerous authors stated that *S. uberis* produces clinical and subclinical cases of mastitis [e.g. 58,59], being classified as an

environment-associated, major pathogen. According to Hillerton and Berry [60], environmental streptococci are responsible for one third of clinical mastitis cases. *S. uberis* enters the udder via the teat canal, and high bacterial counts in the environment raise the infection rate [35].

Reports on the duration of the infection vary considerably. While most infections are relatively short (16 to 46 days; [19,61]), some authors described prolonged periods from 2 to 20 months [43,62,63].

The infection rate of subclinically-diseased quarters seems to be low, even in herds in which *S. uberis* is the most prevalent pathogen of clinical mastitis. Accordingly, Tenhagen et al. [64] detected *S. uberis* in only 1% of quarters sampled in the German federal state of Brandenburg. Zadoks et al. [65] showed that in older cows, prevalence increased with the lactation stage, while during early lactation, there were no significant differences between primiparous and multiparous cows.

On the contrary Piepers et al. [66] pointed out that aesculin-positive cocci including *S. uberis* have become more important as cause of subclinical mastitis. Analysing quarter-milk samples obtained from Belgian dairy cows during cross-sectional dairy herd screenings performed between 2000 and 2002, they found a herd prevalence of aesculin-positive cocci of 2,6% (0-21,7%).

If *S. uberis* evolves to the leading pathogen of a dairy herd, frequent antimicrobial treatments and a series of environment-associated factors seem to promote the development of this type of mastitis [67,68]. Clinical cases caused by *S. uberis* are closely associated with hygiene conditions, feeding and machine-milking [69].

Teat and udder surface contamination between milkings is the first step for the development of mastitis by *S. uberis*. Construction of the resting areas, the available space per cow, the bedding material and its frequency of renewing, cleaning and disinfection and the time the animal spends in the cubicles are factors that determine the infection between milkings [70]. Sources for *S. uberis* are found in loose housing-as well as in pasture systems and also include water for livestock. Increased bacterial counts in bedding materials contribute to rising infection rates which are maximized during warm seasons [61,71].

Previous and persisting infections favour new infections. After the infection by *S. uberis* had healed, an increased risk of reinfection (particularly by *S. uberis*) was observed [65]. The infection rates were also increased if quarters were affected by *Trueperella pyogenes*, enterococci or *S. aureus*.

Infections with minor pathogens such as *Corynebacterium (C.) bovis* were thought, for a long time, to reduce the risk of becoming affected by *S. uberis*. However, Hogan et al. [72] could demonstrate that udder inflammations due to environmental streptococci were 3.9 times more frequent in quarters infected by *C. bovis* than in uninfected ones; regarding *staphylococci*, the infection risk increased by the factor 2.6. To explain this difference to the common assumption, the authors referred to the elevated sampling frequency and to the fact, that 69% of infections with *S. uberis* last fewer than 30 days.

Apart from the transmission by means of the contamination of teat and udder skin between milkings, Zadoks et al. [50] suggested a contagious way of transmission. The pathogen could be detected in a milk swab sample from a liner rubber directly after milking a cow infected with *S. uberis* [18]. Chronically affected animals could contribute particularly to the transmission of the bacterium during

milking [73]. As stated above, *S. uberis* could also be isolated from the oral cavity, so that reciprocal sucking of the teats might also pose one risk of infection [74]. According to Smith et al. [71], the new infection rate rises by the factor of 5 between the first and the fourth lactation. The results of Zadoks et al. [65] support these finding by stating that the infection rate regarding environmental streptococci is lower in animals of the first and second lactation than in older animals.

Zadoks et al. [65] did not find a relation between teat end roughness and *S. uberis* mastitis. In contrast, Breen et al. [75] showed that very rough callous rings increase the risk of clinical *S. uberis* mastitis. Furthermore, the absence of callous rings may be associated with an increased mastitis risk. Paduch et al. [48] could show that the teat canal microbial load of *S. uberis* is associated with teat end hyperkeratosis. In the study of Moyes et al. [76] regarding the negative energy balance, udders were infected experimentally with *S. uberis*. One result was that most genes necessary for the modulation of an immune response were suppressed in the case of animals that presented a negative energy balance. However, no significant associations between body condition score (BCS) and infection rate [65] or clinical mastitis risk [75] for *S. uberis* were found. No further details are known regarding the specific interaction between this pathogen and tissue damages produced by inadequate machine milking except that there is a relation between the degree of hyperkeratosis of the teat tip and the microbial load of *S. uberis* [48].

### Control of *S. uberis*

Implementing the five-point-plan developed by Bramley and Dodd [46] to control contagious mastitis (i.e. teat disinfection after milking, dry-off using antibiotics, culling of animals resistant to therapy, therapy of clinical mastitis, maintenance and correct application of the milking machine) affects udder health only marginally in cases where the pathogen is environment-associated [77]. This implies that treatment measures only are not enough to improve the situation of infections.

The goal is rather to minimize the exposure of the teat canal to *S. uberis*. This is obtained by an optimisation of the environment hygiene and the udder preparation. Concerning the latter however, it remains unclear what precisely improves the status of the infection. Hogan et al. [72] focused on the inhibiting interaction between *S. uberis* and *C. bovis* (see above), which would suggest that a high degree of hygiene at milking may reduce the colonization of the teat skin with environment *streptococci* and *C. bovis* alike. Thus, the protective effect of *C. bovis* would be diminished (as would be the risk of getting infected via teat skin contamination). An udder preparation including humidified, single-use udder towels or a pre-dipping with 0.1% iodophor solution can achieve a significant reduction of the infection rate [78], with pre-dipping being more effective than udder towels soaked in water.

Teat disinfection after milking reduces the prevalence of new infections with *S. agalactiae* and *S. aureus*, but not that of other streptococci [79].

Godinho and Bramley [80] investigated the efficiency of post-milking, dipping disinfectants containing ethanol, iodophores or chlorhexidin on teats which previously had been contaminated with *S. uberis* and *Escherichia coli*. All substances displayed a bactericidal effect, but the persistency of this effect on the teat surface varied. According to this study, a long persistence is beneficial to control environmental pathogens.

The cows' coat may be contaminated with *S. uberis* and, since reciprocal licking is part of the social behaviour of the animals, the pathogen may be distributed readily from one animal to another. Clipping the udder of the animals reduces the surface available for pathogens, and frequent clipping was associated with low bulk SCC [69]. The same is true for providing clean water for drinking. Zadoks et al. [14] encountered *S. uberis* in water and faeces at irregular intervals, so an oral infection seems possible.

Improving the hygienic conditions of the cows also includes the maintenance of the cubicles and the choice of an adequate bedding material. Zadoks et al. [50] postulated that bedding management may play a role in outbreaks of *S. uberis* mastitis. As stated by Hughes [52], *S. uberis* is not able to grow in bedding materials at pH values above 9.5. Paduch et al. [45] showed that the alkalisation of sawdust bedding reduces teat skin bacterial counts of *S. uberis*. However, associations between the alkalisation and teat canal bacterial counts could not be found for *S. uberis*. In general, environmental pathogens like *S. uberis* and *E. coli* could be controlled by teat cleaning before milking and housing and bedding management practices [81].

If reducing the risk of exposition is one way to reduce the new infection rate, improving the immune status of the animals is another one. As concluded by O'Rourke [81], deficiencies in nutrition are generally associated with the suppression of the immune system which promotes the risk of clinical mastitis. According to a study of Todhunter et al. [61], approx. 50.5% of intramammary infections initiate during the dry period, just as Smith et al. [71] recorded more infections during dry period than during lactation. Applying dry cow treatment is effective to reduce the number of infections by *S. uberis*, especially during the first quarter of the dry period [71]. Therefore, in order to maintain a high level of protection also during the rest of the period, measures beyond drying-off with antibiotics will be necessary. Prepartum teat disinfection with an iodophore dip alone however was not sufficient [82].

Cattell [73] in turn claimed that *S. uberis* as a herd problem originates from a bad choice of dry-off substance and omitting to treat clinical cases. This leads to chronic infections that serve as a reservoir for reinfection which ultimately will increase the presence of the pathogen in the environment. To cope with the latter, the author recommends thorough stripping extraction including a control of this secretion, an adaption of the dry management and the treatment of clinical cases during lactation.

## Therapy

Typically, penicillin-based products are used to treat udders affected by *S. uberis*, although in some areas, only 75% of strains are still sensible towards them [43]. Macrolides and cephalosporins are used as an alternative. In Northern Germany, a survey regarding the antimicrobial resistance patterns of pathogens from quarter foremilk samples between 2004 and 2010, no in vitro resistance was found towards penicillin, ampicillin, oxacillin, cefquinome, amoxicillin/clavulanic acid nor cefazolin. Resistance against cefoperazone was <1%, against pirlimycin and erythromycin approx. 30%, and the percentage of strains resistant against tetracyclins rose from <1 to >50% [83].

Treating subclinical cases during lactation lead to a reduction of the somatic cell counts, but animals remain more susceptible towards reinfections. This is why treatments during the lactation are recommended for clinical cases only [84].

As *S. uberis* colonizes the ducts before spreading into the mammary parenchyma, intra-cisternal treatment is the treatment of choice. While Sandgren et al. [84] could not find any statistical difference between parenteral and local treatments (five days each), Hillerton and Kliem [85] were able to obtain the best results by applying a sufficient dose of antibiotics intra-cisternally over a prolonged time. Another study [86] treated clinical mastitis due to streptococci using either parenteral applications of penethamate hydroiodine or a combination of cloxacillin and ampicillin locally, each for three days. The bacteriological healing rates were 71 and 74%, resp., i.e. comparable values to those obtained by Hillerton and Kliem [85]. Although these rates did not differ significantly, the parenteral application lead to a reduction of high somatic cell counts in adjacent, culture-negative quarters.

Several studies demonstrated that the extension of the therapy is advantageous [85,87-90]. Oliver et al. [88,90] investigated the effect of time using the third-generation cephalosporin ceftiofur to treat *S. uberis* mastitis for two, five, and eight days. Bacterial cure rates for naturally-occurring, subclinical cases were to 17, 56, and 67%, resp. (no significant differences), while for experimental infections treated intra-cisternally, values were 43, 88 and 100%, respectively. However, in the last trial the somatic cell counts were only reduced when a bacteriological cure had actually taken place.

Hillerton and Kliem [85] also infected cows experimentally with this pathogen. If the clinical cases were left untreated, parenchyma tissue damage was extreme and lead to the loss of the given quarter. If an intensive local treatment (three days, twice a day) was initiated, clinical cure rates amounted to 70% (after three days) and even 100% (after six days). Using a similar design (but with procaine penicillin and dihydrostreptomycin applied parenterally) lead to clinical cure rates of 18 and 91%, respectively. Bacteriological cure was obtained in 80% of quarters in both designs. By combining local and parenteral treatment, clinical cure rates were 61 and 100%, respectively. However, the bacteriological cure rate of 72% ranged below the values obtained for the single treatments. One intra-cisternal application per day over a period of three days reduced clinical (27 and 91%, resp.) and bacteriological cure rates (64%) alike.

Administering oxytocin intramuscularly twice a day for three days as an alternative did not produce any clinical cure, neither alone nor in combination with a once-a-day intra-cisternal treatment with antibiotics. Even after six days, this treatment combination only yielded 10% of clinical healing.

McDougall et al. [91] applied 5 g tylosin base daily for three days and obtained a bacteriological healing in 89.8% of quarters. 87.7% of quarters were healed if 5 g of penethamate hydroiodine were used instead; results did not differ significantly.

Cattell et al. [92] applied lincosamides (pirlimycin hydrochlorine) daily for two days into the cistern to treat clinical and subclinical mastitis due to streptococci and obtained bacteriological cure rates of 48% (cow level) and 70% (udder level).

As demonstrated by Hillerton and Kliem [85], applying oxytocin alone to treat clinical cases by *S. uberis* is unsatisfactory. 20 IU of this hormone administered to cows with a suspected case of mastitis eliminated 25% of cases; thus, 75% of animals still developed clinical mastitis [93]. Comparing three consecutive intracisternal applications of antibiotics (at each milking time i. e. over a period of 1,5 days) with 10 applications (i. e. over a period of 5 days) the prolonged treatment

regimen leads in cases of moderate and severe clinical mastitis cases to higher bacteriological and cytological cleaning rates [89].

In a study of Roberson et al. [94] frequent milk-out appeared to be detrimental for managing mild to moderate clinical mastitis caused by environmental streptococci.

### Dry cow treatment

As stated above, new infections are most frequent during the dry period, and dry-off treatment leads to a marked reduction of problems during the first phase of the dry period. Cure rates of 87 to 95% were observed when administering semi-synthetic penicillins [43]. Yet, the last two weeks remain unprotected (in many cases, the teat canal open up, the keratin plug gets lost and the periparturient immune suppression commences).

Usage of dry cow antibiotics plays an important role in the reduction of mastitis incidence due to *S. uberis*. In a study of Williamson et al. [59] the administration of a dry cow antibiotic to uninfected quarters reduced the incidence of new infections with *S. uberis* from 12.3% (untreated quarter) to 1.2% (treated quarter). This reduction was significant for dry-period as well as post-calving infections.

Furthermore the usage of external or internal teat sealer should lower the infection rate with environmental germs like *S. uberis* and *E. coli*. Lim et al. [95,96] showed that the efficiency of an external teat sealer varies with the time frame of adherence (longer adherence on longer teats, in cold climate or after double application). In the review of Rabiee and Lean [97], internal teat sealer alone or in combination with antibiotic dry cow therapy reduced the risk of acquiring new intramammary infections after calving by 25%. Compared with untreated cows, internal teat sealer reduced the risk by 73% although there could be stated a huge heterogeneity in the results. The reduction of clinical mastitis was calculated with 29% and 48%.

### Vaccination

Since Hill [98] showed that previous exposure to *S. uberis* could provide some resistance to infection against the same strain, several trials with a broad variety in efficiency were performed to identify potential vaccine candidates against *S. uberis* mastitis: i. e. the plasminogen activator PauA as a total antigen as well as a PauA depleted antigen [99], recombinant *S. uberis* GapC or a chimeric CAMP antigen [100], recombinant *S. uberis* adhesion molecule [101] as well as *S. uberis* bacterin [102] etc. Until now there is still a lack of vaccine which is able to control infection without the participation of a marked inflammatory response.

### Conclusion

Controlling *S. uberis*-infections remains an important task. The germ is commonly found in manure and other organic matter. Inadequate stall or pasture management e. g. dirty and wet bedding material or muddy areas as well as improper milking procedures lead to an increased infection risk. As infections are difficult to cure, emphasis needs to be placed on prevention of these infections. Still further research is necessary to allow a ranking of management methods regarding their efficiency to reduce contamination with these bacteria.

### References

1. Diernhofer K (1932) Aesculinbouillon als Hilfsmittel für die Differenzierung von Euter- und Milchstreptokokken bei Massenuntersuchungen. Milchw Forsch 13: 368-374.
2. Lancefield RC (1933) A serological differentiation of human and other groups of hemolytic streptococci. J Exp Med 57: 571-595.
3. Hassan AA, Akineden O, Usleber E (2005) Identification of *Streptococcus canis* isolated from milk of dairy cows with subclinical mastitis. J Clin Microbiol 43: 1234-1238.
4. Facklam R (2002) What happened to the streptococci: overview of taxonomic and nomenclature changes. Clin Microbiol Rev 15: 613-630.
5. Täpp J, Tholleson M, Herrmann B (2003) Phylogenetic relationships and genotyping of the genus *Streptococcus* by sequence determination of the RNase P RNA gene, rnpB. Int J Syst Evol Microbiol 53: 1861-1871.
6. Williams AM, Collins MD (1990) Molecular taxonomic studies on *Streptococcus uberis* types I and II. Description of *Streptococcus parauberis* sp. nov. J Appl Bacteriol 68: 485-490.
7. Bramley AJ (1984) *Streptococcus uberis* udder infection--a major barrier to reducing mastitis incidence. Br Vet J 140: 328-335.
8. Lämmle C (1991) Biochemical and serological properties of *Streptococcus uberis*. Zentralbl Veterinarmed B 38: 737-742.
9. Odierno L, Calvino L, Traversa P, Lasagno M, Boglietti C, et al. (2006) Conventional identification of *Streptococcus uberis* isolated from bovine mastitis in Argentinean dairy herds. J Dairy Sci 89: 3886-3890.
10. Garvie EI, Bramley AJ (1979) *Streptococcus uberis*: an approach to its classification. J Appl Microbiol 46: 295-304.
11. Khan IU, Hassan AA, Abdulmawjood A, Lämmle C, Wolter W, et al. (2003) Identification and epidemiological characterization of *Streptococcus uberis* isolated from bovine mastitis using conventional and molecular methods. J Vet Sci 4: 213-224.
12. Hardie JM (1986) Other streptococci. In: Sneath PHA (ed.) *Bergey's Manual of Systematic Bacteriology*. Volume 2. Williams and Wilkins, Baltimore, Hong Kong, London, Munich, Philadelphia, San Francisco, Sydney, Tokyo: 1068-1071.
13. Watts JL, Salmon SA, Yancey RJ Jr (1993) Use of modified Rambach agar to differentiate *Streptococcus uberis* from other mastitis streptococci. J Dairy Sci 76: 1740-1743.
14. Zadoks RN, Middleton JR, McDougall S, Katholm J, Schukken YH (2011) Molecular epidemiology of mastitis pathogens of dairy cattle and comparative relevance to humans. J Mammary Gland Biol Neoplasia 16: 357-372.
15. Zadoks RN, Schukken YH, Wiedmann M (2005) Multilocus sequence typing of *Streptococcus uberis* provides sensitive and epidemiologically relevant subtype information and reveals positive selection in the virulence gene pauA. J Clin Microbiol 43: 2407-2417.
16. Forsman P, Tilsala-Timisjärvi A, Alatosava T (1997) Identification of staphylococcal and streptococcal causes of bovine mastitis using 16S-23S rRNA spacer regions. Microbiology 143: 3491-3500.
17. Riffon R, Sayasith K, Khalil H, Dubreuil P, Drolet M, et al. (2001) Development of a rapid and sensitive test for identification of major pathogens in bovine mastitis by PCR. J Clin Microbiol 39: 2584-2589.
18. Zadoks RN, Gillespie BE, Barkema HW, Sampimon OC, Oliver SP, et al. (2003) Clinical, epidemiological and molecular characteristics of *Streptococcus uberis* infections in dairy herds. Epidemiol Infect 130: 335-349.
19. McDougall S, Parkinson TJ, Leyland M, Anniss FM, Fenwick SG (2004) Duration of infection and strain variation in *Streptococcus uberis* isolated from cows' milk. J Dairy Sci 87: 2062-2072.
20. Rato MG, Bexiga R, Nunes SF, Cavaco LM, Vilela CL, et al. (2008) Molecular epidemiology and population structure of bovine *Streptococcus uberis*. J Dairy Sci 91: 4542-4551.
21. Coffey TJ, Pullinger GD, Urwin R, Jolley KA, Wilson SM, et al. (2006) First insights into the evolution of *Streptococcus uberis*: a multilocus

- sequence typing scheme that enables investigation of its population biology. Appl Environ Microbiol 72: 1420-1428.
22. Tomita T, Meehan B, Wongkattiya N, Malmo J, Pullinger G, et al. (2008) Identification of *Streptococcus uberis* multilocus sequence types highly associated with mastitis. Appl Environ Microbiol 74: 114-124.
  23. Hassan AA, Khan IU, Abdulmawjood A, Lämmler C (2001) Evaluation of PCR methods for rapid identification and differentiation of *Streptococcus uberis* and *Streptococcus parauberis*. J Clin Microbiol 39: 1618-1621.
  24. Schaufuss P, Sting R, Schaeg W, Blobel H (1989) Isolation and characterization of hyaluronidase from *Streptococcus uberis*. Zentralbl Bakteriell 271: 46-53.
  25. Matthews KR, Oliver SP (1993) Encapsulation of streptococci isolated from bovine milk. Zentralbl Veterinarmed B 40: 597-602.
  26. Matthews KR, Almeida RA, Oliver SP (1994) Bovine mammary epithelial cell invasion by *Streptococcus uberis*. Infect Immun 62: 5641-5646.
  27. Ditcham WG, Leigh JA, Bland AP, Hill AW (1996) Adhesion of *Streptococcus uberis* to monolayers of cultured epithelial cells derived from the bovine mammary gland. FEMS Immunol Med Microbiol 14: 145-150.
  28. Oliver SP, Almeida RA, Calvino LF (1998) Virulence factors of *Streptococcus uberis* isolated from cows with mastitis. Zentralbl Veterinarmed B 45: 461-471.
  29. Almeida RA, Luther DA, Patel D, Oliver SP (2011) Predicted antigenic regions of *Streptococcus uberis* adhesion molecule (SUAM) are involved in adherence to and internalization into mammary epithelial cells. Vet Microbiol 148: 323-328.
  30. Frost AJ, Wanasinghe DD, Woolcock JB (1977) Some factors affecting selective adherence of microorganisms in the bovine mammary gland. Infect Immun 15: 245-253.
  31. Crowley RC, Leigh JA, Ward PN, Lappin-Scott HM, Bowler LD (2011) Differential protein expression in *Streptococcus uberis* under planktonic and biofilm growth conditions. Appl Environ Microbiol 77: 382-384.
  32. Fang W, Oliver SP (1999) Identification of lactoferrin-binding proteins in bovine mastitis-causing *Streptococcus uberis*. FEMS Microbiol Lett 176: 91-96.
  33. Lasagno MC, Reinoso EB, Dieser SA, Calvino LF, Buzzola F, et al. (2011) Phenotypic and genotypic characterization of *Streptococcus uberis* isolated from bovine subclinical mastitis in Argentinean dairy farms. Rev Argent Microbiol 43: 212-217.
  34. Tassi R, McNeilly TN, Fitzpatrick JL, Fontaine MC, Reddick D, et al. (2013) Strain-specific pathogenicity of putative host-adapted and nonadapted strains of *Streptococcus uberis* in dairy cattle. J Dairy Sci 96: 5129-5145.
  35. Wendt K, Lotthammer KH, Fehlings K, Spohr M (1998) Handbuch Mastitis. Verlag Klammer, Osnabrück, Germany.
  36. Krömker V, Bruckmaier R, Frister H, Kützemeier T, Rudzik L, et al. (2007) Short textbook milk and milk hygiene. Parey Verlag Stuttgart.
  37. Beerwerth W, Köser A (1965) Streptokokken verschiedener serologischer Gruppen als Mastitiserreger und ihr Vorkommen außerhalb des Rindereuters. Band 6 von Bibliotheca lactis. Milchwissenschaft 20: 590-593.
  38. Cullen GA (1966) The ecology of *Streptococcus uberis*. Br Vet J 122: 333-339.
  39. Winkenwerder W (1966) Vorkommen und Bedeutung der sog. nichthaemolysierenden Streptokokken im Genitaltrakt von Rindern. Reprod Domest Anim 4: 170-174.
  40. Daleel EE, Frost AJ (1967) Some observations on the bacterial flora of the bovine tonsil. Br Vet J 123: 232-236.
  41. Cullen GA (1969) Isolation of *Str. uberis* from lactating and non-lactating cows. Br Vet J 125: 145-149.
  42. Bramley AJ (1982) Sources of *Streptococcus uberis* in the dairy herd. I. Isolation from bovine faeces and from straw bedding of cattle. J Dairy Res 49: 369-373.
  43. Hejlicek K (1994) Mastitis durch *Streptococcus agalactiae* (Gelber Galt). In: Wendt K, Bostedt H, Mielke H, Fuchs HW (eds.): Euter- und Gesäugekrankheiten Gustav Fischer Verlag, Jena, Stuttgart.
  44. Wendt K, Bostedt H, Mielke H, Fuchs HW (1994) Euter- und Gesäugekrankheiten. Gustav Fischer Verlag Jena, Stuttgart.
  45. Paduch JH, Mohr E, Krömker V (2013) The association between bedding material and the bacterial counts of *Staphylococcus aureus*, *Streptococcus uberis* and coliform bacteria on teat skin and in teat canals in lactating dairy cattle. J Dairy Res 80: 159-164.
  46. Bramley AJ, Dodd FH (1984) Reviews of the progress of dairy science: mastitis control - progress and prospects. J Dairy Res 51: 481-512.
  47. Pryor SM (2008) Bovine mastitis and ecology of *Streptococcus uberis*. Ph.D. thesis, University of Waikato, New Zealand.
  48. Paduch JH, Mohr E, Krömker V (2012) The association between teat end hyperkeratosis and teat canal microbial load in lactating dairy cattle. Vet Microbiol 158: 353-359.
  49. Fecteau G, Baillargeon P, Higgins R, Paré J, Fortin M (2002) Bacterial contamination of colostrum fed to newborn calves in Québec dairy herds. Can Vet J 43: 523-527.
  50. Zadoks RN, Allore HG, Barkema HW, Sampimon OC, Gröhn YT, et al. (2001) Analysis of an outbreak of *Streptococcus uberis* mastitis. J Dairy Sci 84: 590-599.
  51. Browning JW, Mein GA, Barton M, Nicholls TJ, Brightling P (1990) Effects of antibiotic therapy at drying off on mastitis in the dry period and early lactation. Aust Vet J 67: 440-442.
  52. Hughes J (1999) Bedding systems and mastitis. Proceedings of British Mastitis Conference.
  53. Wilkinson A (2003) To seal or not to seal: internal teat sealant strategies. Proceedings of National Mastitis Council Regional Meeting.
  54. Phuektes P, Mansell PD, Dyson RS, Hooper ND, Dick JS, et al. (2001) Molecular epidemiology of *Streptococcus uberis* isolates from dairy cows with mastitis. J Clin Microbiol 39: 1460-1466.
  55. Wellnitz O, Kerr DE (2004) Cryopreserved bovine mammary cells to model epithelial response to infection. Vet Immunol Immunopathol 101: 191-202.
  56. Wellnitz O, Reith P, Haas SC, Meyer HHD (2006) Immune relevant gene expression of mammary epithelial cells and their influence on leukocyte chemotaxis in response to different mastitis pathogens. Vet Med-Czech 51: 125-132.
  57. Barber MR, Yang TJ (1998) Chemotactic activities in nonmastitic and mastitic mammary secretions: presence of interleukin-8 in mastitic but not nonmastitic secretions. Clin Diagn Lab Immunol 5: 82-86.
  58. Hogan JS, Smith KL, Hoblet KH, Schoenberger PS, Todhunter DA, et al. (1989) Field survey of clinical mastitis in low somatic cell count herds. J Dairy Sci 72: 1547-1556.
  59. Williamson JH, Woolford MW, Day AM (1995) The prophylactic effect of a dry-cow antibiotic against *Streptococcus uberis*. N Z Vet J 43: 228-234.
  60. Hillerton JE, Berry EA (2003) The management and treatment of environmental streptococcal mastitis. Vet Clin North Am Food Anim Pract 19: 157-169.
  61. Todhunter DA, Smith KL, Hogan JS (1995) Environmental streptococcal intramammary infections of the bovine mammary gland. J Dairy Sci 78: 2366-2374.
  62. Lam TJGM (1996) Dynamics of bovine mastitis: a field study in low somatic cell count herds. Ph.D. thesis, Utrecht University, The Netherlands.
  63. Watt CJ (1999) The epidemiology of intramammary infection in dairy cows, with particular reference to *Streptococcus uberis*. Ph.D. thesis, University of Oxford, UK.
  64. Tenhagen BA, Köster G, Wallmann J, Heuwieser W (2006) Prevalence of mastitis pathogens and their resistance against antimicrobial agents in dairy cows in Brandenburg, Germany. J Dairy Sci 89: 2542-2551.

65. Zadoks RN, Allore HG, Barkema HW, Sampimon OC, Wellenberg GJ, et al. (2001) Cow- and quarter-level risk factors for *Streptococcus uberis* and *Staphylococcus aureus* mastitis. J Dairy Sci 84: 2649-2663.
66. Piepers S, De Meulemeester L, de Kruif A, Opsomer G, Barkema HW, et al. (2007) Prevalence and distribution of mastitis pathogens in subclinically infected dairy cows in Flanders, Belgium J Dairy Res 74: 478-483.
67. King JS (1981) *Streptococcus uberis*: a review of its role as a causative organism of bovine mastitis. I. Characteristics of the organism. Br Vet J 137: 36-52.
68. King JS (1981) *Streptococcus uberis*: a review of its role as a causative organism of bovine mastitis. II. Control of infection. Br Vet J 137: 160-165.
69. Barkema HW, Schukken YH, Lam TJ, Beiboer ML, Benedictus G, et al. (1999) Management practices associated with the incidence rate of clinical mastitis. J Dairy Sci 82: 1643-1654.
70. Bramley AJ (1985) The sources of mastitis pathogens for a dairy herd and their control. Kieler Milchwirtsch Forschungsber 37: 375-380.
71. Smith KL, Todhunter DA, Schoenberger PS (1985) Environmental mastitis: cause, prevalence, prevention. J Dairy Sci 68: 1531-1553.
72. Hogan JS, Smith KL, Todhunter DA, Schoenberger PS (1988) Rate of environmental mastitis in quarters infected with *Corynebacterium bovis* and *Staphylococcus* species. J Dairy Sci 71: 2520-2525.
73. Cattell MB (1996) An outbreak of *Streptococcus uberis* as a consequence of adopting a protocol of no antibiotic therapy for clinical mastitis. Proceedings of National Mastitis Council Annual Meeting.
74. Cruz Colque JI, Devriese LA, Haesebrouck F (1993) Streptococci and enterococci associated with tonsils of cattle. Lett Appl Microbiol 16: 72-74.
75. Breen JE, Green MJ, Bradley AJ (2009) Quarter and cow risk factors associated with the occurrence of clinical mastitis in dairy cows in the United Kingdom. J Dairy Sci 92: 2551-2561.
76. Moyes KM, Drackley JK, Morin DE, Rodriguez-Zas SL, Everts RE, et al. (2010) Mammary gene expression profiles during an intramammary challenge reveal potential mechanisms linking negative energy balance with impaired immune response. Physiol Genomics 41: 161-170.
77. Leigh JA (1999) *Streptococcus uberis*: a permanent barrier to the control of bovine mastitis? Vet J 157: 225-238.
78. Galton DM, Peterson LG, Merrill WG (1988) Evaluation of udder preparations on intramammary infections. J Dairy Sci 71: 1417-1421.
79. Smith KL (1983) Mastitis control: a discussion. J Dairy Sci 66: 1790-1794.
80. Godinho KS, Bramley AJ (1980) The efficacy of teat dips of differing persistence on teat skin in preventing intramammary infection by *Streptococcus uberis* and *Escherichia coli* in dry cows. Br Vet J 136: 574-579.
81. O'Rourke D (2009) Nutrition and udder health in dairy cows: a review. Ir Vet J 62 Suppl 4: S15-20.
82. Schultze WD (1985) Control of new intramammary infection at calving by prepartum teat dipping. J Dairy Sci 68: 2094-2099.
83. Grabowski NT, Alfeld B, Klein G (2012) Eutergesundheit aus Sicht eines Diagnostiklabors. J Food Safety Food Quality 62: 89-91.
84. Sandgren CH, Waller KP, Emanuelson U (2008) Therapeutic effects of systemic or intramammary antimicrobial treatment of bovine subclinical mastitis during lactation. Vet J 175: 108-117.
85. Hillerton JE, Kliem KE (2002) Effective treatment of *Streptococcus uberis* clinical mastitis to minimize the use of antibiotics. J Dairy Sci 85: 1009-1014.
86. Sérieys F, Raguét Y, Goby L, Schmidt H, Friton G (2005) Comparative efficacy of local and systemic antibiotic treatment in lactating cows with clinical mastitis. J Dairy Sci 88: 93-99.
87. Pyörälä S. (2006) Treatment of clinical mastitis: local and/or systemic? Short or long?. Proceedings of 24th World Buiatrics Congress.
88. Oliver SP, Gillespie BE, Headrick SJ, Moorehead H, Lunn P, et al. (2004) Efficacy of extended ceftiofur intramammary therapy for treatment of subclinical mastitis in lactating dairy cows. J Dairy Sci 87: 2393-2400.
89. Krömker V, Paduch JH, Klocke D, Friedrich J, Zinke C (2010) Wirksamkeit einer verlängerten Arzneimittelapplikation zur Behandlung mittel- und hochgradiger klinischer Mastitiden bei Milchkühen. Berl. Münch. Tierärztl. Wochenschr 123: 147-152.
90. Oliver SP, Almeida RA, Gillespie BE, Headrick SJ, Dowlen HH, et al. (2004) Extended ceftiofur therapy for treatment of experimentally-induced *Streptococcus uberis* mastitis in lactating dairy cattle. J Dairy Sci 87: 3322-3329.
91. McDougall S, Agnew KE, Cursons R, Hou XX, Compton CR (2007) Parenteral treatment of clinical mastitis with tylosin base or penethamide hydriodide in dairy cattle. J Dairy Sci 90: 779-789.
92. Cattell MB, Dinsmore RP, Belschner AP, Carmen J, Goodell G (2001) Environmental gram-positive mastitis treatment: in vitro sensitivity and bacteriologic cure. J Dairy Sci 84: 2036-2043.
93. Hillerton JE, Semmens JE (1999) Comparison of treatment of mastitis by oxytocin or antibiotics following detection according to changes in milk electrical conductivity prior to visible signs. J Dairy Sci 82: 93-98.
94. Roberson JR., Warnick LD, Moore M (2004) Mild to moderate clinical mastitis: efficacy of intramammary amoxicillin, frequent milk-out, a combined intramammary amoxicillin, and frequent milk-out treatment versus no treatment. J. Dairy Sci. 87: 583-592.
95. Lim GH, Leslie KE, Kelton DF, Duffield TF, Timms LL, et al. (2007) Adherence and efficacy of an external teat sealant to prevent new intramammary infections in the dry period. J Dairy Sci 90: 1289-1300.
96. Lim GH, Kelton DF, Leslie KE, Timms LL, Church C, et al. (2007) Herd management factors that affect duration and variation of adherence of an external teat sealant. J Dairy Sci 90: 1301-1309.
97. Rabiee AR, Lean IJ (2013) The effect of internal teat sealant products (Teatseal and Orbeseal) on intramammary infection, clinical mastitis, and somatic cell counts in lactating dairy cows: a meta-analysis. J Dairy Sci 96: 6915-6931.
98. Hill AW (1988) Protective effect of previous intramammary infections with *Streptococcus uberis* against subsequent clinical mastitis in the cow. Research in Veterinary Science 44: 386-391.
99. Leigh JA, Finch JM, Field TR, Real NC, Winter A, et al. (1999) Vaccination with the plasminogen activator from *Streptococcus uberis* induces an inhibitory response and protects against experimental infection in the dairy cow. Vaccine 17: 851-857.
100. Fontaine MC, Perez-Casal J, Song x-M, Shelford J, Willson PJ, et al. (2002) Immunisation of dairy cattle with recombinant *Streptococcus uberis* GapC or a chimeric CAMP antigen confers protection against heterologous bacterial challenge. Vaccine 20: 2278-2286.
101. Prado ME, Almeida RA, Ozen C, Luther DA, Lewis MJ, et al. (2011) Vaccination of dairy cows with recombinant *Streptococcus uberis* adhesion molecule induces antibodies that reduce adherence to and internalization of *S. uberis* into bovine mammary epithelial cells. Vet Immunol Immunopathol 141: 201-208.
102. Wallis DM (2013) Case study: reduction in bulk tank somatic cell count on a commercial dairy associated with use of a *Streptococcus uberis* bacterin, 52nd Annual Meeting, San Diego, California; Proceedings: 219-220.